StreetInsider.com News Articles

Revive Therapeutics closes first tranche of private placement

Wed, 15 Jul 2026 18:40:10 -0400

Revive Therapeutics Ltd. (OTCQB: RVVTF)(CSE: RVV) closed the first tranche of a non-brokered private placement, raising gross proceeds of $246,920, according to a press release dated July 15, 2026.

The placement involved the issuance of 7,716,250 units at $0.032 per unit. Each unit consists of one common share and one warrant, with each warrant exercisable at $0.05 per share for 36 months from the closing date.

The company said it intends to use the proceeds primarily for working capital purposes.

In connection with the closing, Revive paid finders fees totaling $17,433.60 and issued 537,300 broker warrants, each exercisable at $0.05 per common share

Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Wed, 15 Jul 2026 18:40:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

TORONTO, ON / ACCESS Newswire / July 15, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, announces that it has closed the first tranche of its previously announced non-brokered private placement for gross proceeds of $246,920 (the "Private Placement").

The Private Placement consisted of the issuance and sale of 7,716,250 units of the Company ("Units"), at a price of $0.032 per Unit. Each Unit issued pursuant to

Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Wed, 15 Jul 2026 18:40:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

The Private Placement consisted of the issuance and sale of 7,716,250 units of the Company ("Units"), at a price of $0.032 per Unit. Each Unit issued pursuant to

Revive Therapeutics proposes $1M private placement

Fri, 26 Jun 2026 16:16:12 -0400

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) is proposing a private placement of up to 31,250,000 units at $0.032 per unit, seeking gross proceeds of up to approximately $1,000,000, according to a company statement.

Each unit will consist of one common share and one common share purchase warrant. Each warrant will allow the holder to acquire one additional common share at an exercise price of $0.05 for 36 months following the closing date. The unit price is based on the 20-day volume-weighted average price of shares traded on the Canadian Securities Exchange.

Finders involved in the placement will receive a cash fee

Revive Therapeutics Announces Proposed Private Placement

Fri, 26 Jun 2026 16:15:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

TORONTO, ON / ACCESS Newswire / June 26, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, announces that it is proposing to arrange a private placement of up to 31,250,000 units of the Company ("Units"), at a price of $0.032 per Unit for gross proceeds to Revive of up to approximately $1,000,000 (the "Private Placement").

Each Unit will consist of one common share of the Company (a

Revive Therapeutics Announces Proposed Private Placement

Fri, 26 Jun 2026 16:15:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Each Unit will consist of one common share of the Company (a

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

Wed, 20 May 2026 07:45:00 -0400

Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future pandemics and medical countermeasure stockpiling

TORONTO, ON / ACCESS Newswire / May 20, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, today announced its strategic expansion plan for bucillamine across infectious disease, defence and biothreat-related applications.

Revive believes bucillamine represents a differentiated strategic asset with potential relevance across multiple high-need areas, including infectious diseases, future pandemic

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

Wed, 20 May 2026 07:45:00 -0400

Revive believes bucillamine represents a differentiated strategic asset with potential relevance across multiple high-need areas, including infectious diseases, future pandemic

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

Wed, 11 Mar 2026 07:30:00 -0400

Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications

TORONTO, ON / ACCESS Newswire / March 11, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, is pleased to announce two important intellectual property milestones for bucillamine: (i) the filing of the U.S. and Canadian national phase patent applications under PCT/CA2024/000008 for "Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent," and (ii) the grant

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

Wed, 11 Mar 2026 07:30:00 -0400

Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study